Cellectis Nom. Stock
Your prediction
Cellectis Nom. Stock
Pros and Cons of Cellectis Nom. in the next few years
Pros
Cons
Performance of Cellectis Nom. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cellectis Nom. | 2.160% | -5.917% | 7.626% | 24.804% | -17.702% | -84.643% | - |
| Valneva SE | -1.800% | -10.343% | -4.477% | -25.833% | -24.387% | -72.640% | 3.029% |
| Nanobiotix | -2.320% | -4.721% | -9.263% | 47.085% | -21.417% | -63.229% | -56.621% |
| Transgene S.A. | 2.690% | 5.985% | 30.811% | -26.741% | 8.358% | -44.368% | -49.671% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Boasting a notable position in the Biotechnology & Medical Research sector, Cellectis, traded under the US symbol, is a company whose financial status merits careful analysis. At first glance, it stands out that the company's financial health is dotted with a mix of promising signs and areas worthy of concern.
On the promising front, the firm's total assets increased to $469,471,000 in 2020 compared to $382,076,000 in 2021, signalling a strong asset base. Despite the subsequent drop in 2022 to $261,216,000, the overall trend shows substantial financial growth. The company’s cash and short-term investments followed a similar pattern, reaching a high of $268,239,000 in 2020.
Moreover, the total revenue of Cellectis also witnessed growth, registering a figure of $73,949,000 in 2020, and growing to $191,710,000 in 2022. The enormous figures for total current assets and gross profit margins, as well as a high EPS (Earnings Per Share), adds an appealing touch to the financial attractiveness of Cellectis.
